Apellis Pharmaceuticals Inc logo

APLS - Apellis Pharmaceuticals Inc Share Price

$43.42 0.4  0.9%

Last Trade - 5:45pm

Sector
Healthcare
Size
Mid Cap
Market Cap £2.42bn
Enterprise Value £2.20bn
Revenue £n/a
Position in Universe 1527th / 6416
Bullish
Bearish
Unlock APLS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APLS Revenue Unlock APLS Revenue

Net Income

APLS Net Income Unlock APLS Revenue

Normalised EPS

APLS Normalised EPS Unlock APLS Revenue

PE Ratio Range

APLS PE Ratio Range Unlock APLS Revenue

Dividend Yield Range

APLS Dividend Yield Range Unlock APLS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APLS EPS Forecasts Unlock APLS Revenue
Profile Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated September 25, 2009
Public Since November 9, 2017
No. of Shareholders: 42
No. of Employees: 87
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 73,438,003
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APLS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APLS
Upcoming Events for APLS
Similar to APLS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.